Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609–52. https://doi.org/10.1007/s00125-021-05568-3.

Article  PubMed  PubMed Central  Google Scholar 

Tauschmann M, Forlenza G, Hood K, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: glucose monitoring. Pediatr Diabetes. 2022;23(8):1390–405. https://doi.org/10.1111/pedi.13451.

Article  PubMed  Google Scholar 

Pozzilli P, Battelino T, Danne T, et al. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32(1):21–39. https://doi.org/10.1002/dmrr.2653.

Article  PubMed  Google Scholar 

Rimon MTI, Hasan MW, Hassan MF, et al. Advancements in insulin pumps: a comprehensive exploration of insulin pump systems, technologies, and future directions. Pharmaceutics. 2024;16(7):944. https://doi.org/10.3390/pharmaceutics16070944.

Article  PubMed  PubMed Central  Google Scholar 

Boughton CK, Hovorka R. The role of automated insulin delivery technology in diabetes. Diabetologia. 2024;67(10):2034–44. https://doi.org/10.1007/s00125-024-06165-w.

Article  PubMed  PubMed Central  Google Scholar 

Renard E, Joubert M, Villard O, et al. Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: a randomized controlled trial. Diabetes Care. 2023;46(12):2180–7. https://doi.org/10.2337/dc23-0685.

Article  PubMed  PubMed Central  Google Scholar 

Boughton CK, Tripyla A, Hartnell S, et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med. 2021;27(8):1471–6. https://doi.org/10.1038/s41591-021-01453-z.

Article  PubMed  PubMed Central  Google Scholar 

Peacock S, Frizelle I, Hussain S. A systematic review of commercial hybrid closed-loop automated insulin delivery systems. Diabetes Ther. 2023;14(5):839–55. https://doi.org/10.1007/s13300-023-01394-5.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: standards of care in diabetes—2025. Diabetes Care. 2024;48(Supplement_1):S146–66. https://doi.org/10.2337/dc25-S007.

Article  Google Scholar 

Chadha M, Jain SM, Chawla R, et al. Evolution of guideline recommendations on insulin therapy in type 2 diabetes mellitus over the last two decades: a narrative review. Curr Diabetes Rev. 2023;19(8):e160123212777. https://doi.org/10.2174/1573399819666230116150205.

Article  PubMed  PubMed Central  Google Scholar 

Anonymous. Open LPP : base complète sur les dépenses de dispositifs médicaux inscrits à la liste des produits et prestations (LPP) - 2014 à 202 https://www.assurance-maladie.ameli.fr/etudes-et-donnees/donnees/liste-bases-de-donnees-open-data. Accessed Feb 19, 2025.

Haute Autorité de Santé. Systèmes de mesure du glucose interstitiel, couplés ou non à une pompe à insuline, et systèmes de boucle semi-fermée pour la gestion automatisée du diabète. Rapport d’évaluation. 2024.

Naïditch N, Hehn C, Thébaut J-F. Pump Support Study. Étude quantitative sur la satisfaction et les besoins des patients diabétiques utilisant une pompe à insuline vis-à-vis de leur prestataire de santé à domicile. Med Mal Metab. 2022;16(4):359–64. https://doi.org/10.1016/j.mmm.2022.02.013.

Article  Google Scholar 

Beltrand J, Benhamou P-Y, Choleau C, et al. Experience of people with diabetes treated with insulin delivery systems in France: a comparative analysis of multiple daily injections, tubeless pumps, tubed pumps, and hybrid closed loops. Diabetes Ther. 2025;16(2):289–306. https://doi.org/10.1007/s13300-024-01682-8.

Article  PubMed  Google Scholar 

Pauley ME, Berget C, Messer LH, et al. Barriers to uptake of insulin technologies and novel solutions. MDER. 2021;14:339–54. https://doi.org/10.2147/MDER.S312858.

Article  Google Scholar 

Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia. 2023;66(1):3–22. https://doi.org/10.1007/s00125-022-05744-z.

Article  PubMed  Google Scholar 

Andrès E, Meyer L, Zulfiqar A-A, et al. Telemonitoring in diabetes: evolution of concepts and technologies, with a focus on results of the more recent studies. J Med Life. 2019;12(3):203–14. https://doi.org/10.25122/jml-2019-0006.

Article  PubMed  PubMed Central  Google Scholar 

Xu Z, Xi X, Wang E. Impact of digital integrated health platforms on diabetes management: evidence from Tianjin, China. BMC Health Serv Res. 2025;25:618. https://doi.org/10.1186/s12913-025-12788-5.

Article  PubMed  PubMed Central  Google Scholar 

Crossen SS, Romero CC, Lewis C, et al. Remote glucose monitoring is feasible for patients and providers using a commercially available population health platform. Front Endocrinol (Lausanne). 2023;14:1063290. https://doi.org/10.3389/fendo.2023.1063290.

Article  PubMed  Google Scholar 

Gaudillère M, Pollin-Javon C, Brunot S, et al. Effects of remote care of patients with poorly controlled type 1 diabetes included in an experimental telemonitoring programme. Diabetes Metab. 2021;47(6):101251. https://doi.org/10.1016/j.diabet.2021.101251.

Article  PubMed  Google Scholar 

Wong JC, Izadi Z, Schroeder S, et al. A pilot study of use of a software platform for the collection, integration, and visualization of diabetes device data by health care providers in a multidisciplinary pediatric setting. Diabetes Technol Ther. 2018;20(12):806–16. https://doi.org/10.1089/dia.2018.0251.

Article  PubMed  PubMed Central  Google Scholar 

Haute Autorité de Santé. Télésurveillance médicale du patient diabétique. Référentiel des fonctions et organisations des soins pour les solutions de télésurveillance médicale du patient diabétique. 2022.

Haute Autorité de Santé. Télésurveillance médicale du patient diabétique. Inscription d’une activité de télésurveillance médicale sous forme générique sur la liste mentionnée à l’article L.162-52 du code de la sécurité sociale. 2023.

Anonymous. Arrêté Du 17 Juillet 2006 Relatif à La Modification de La Nomenclature Relative Aux Pompes à Insuline Externes, Portables et Programmables Inscrites Au Chapitre 1er Du Titre Ier de La Liste Des Produits et Prestations Remboursables Prévue à l’article L. 165-1 Du Code de La Sécurité Sociale - Légifrance. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000000458622/. Accessed Feb 18, 2025.

Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023;11(1):42–57. https://doi.org/10.1016/S2213-8587(22)00319-9.

Article  PubMed  Google Scholar 

Anonymous. GLOOKO XT | Application diabète - Suivi automatique de l’insuline et des glycémies pour les diabétiques. https://glookoxt.com/. Accessed Feb 18, 2025.

Anonymous. myDiabby. https://platform.mydiabby.fr/dt/#/login. Accessed Feb 18, 2025.

Anonymous. LibreView. https://www2.libreview.com/. Accessed Feb 18, 2025.

Franc S, Hanaire H, Benhamou P-Y, et al. Diabeo system combining a mobile app software with and without telemonitoring versus standard care: a randomized controlled trial in diabetes patients poorly controlled with a basal-bolus insulin regimen. Diabetes Technol Ther. 2020;22(12):904–11. https://doi.org/10.1089/dia.2020.0021.

Article  PubMed  PubMed Central  Google Scholar 

Darmon P, Bauduceau B, Bordier L, et al. Prise de position de la Société Francophone du Diabète (SFD) sur les stratégies d’utilisation des traitements anti-hyperglycémiants dans le diabète de type 2–2021. Med Mal Metab. 2021;15(8):781–801. https://doi.org/10.1016/j.mmm.2021.10.014.

Article  Google Scholar 

Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–603. https://doi.org/10.2337/dci19-0028.

Article  PubMed  PubMed Central  Google Scholar 

Riddlesworth TD, Beck RW, Gal RL, et al. Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diabetes Technol Ther. 2018;20(4):314–6. https://doi.org/10.1089/dia.2017.0455.

Article  PubMed  Google Scholar 

Chun E, Broll S, Buchanan D, et al. Iglu: interpreting glucose data from continuous glucose monitors. R package version 3.5.0. 2023.

Chun E, Fernandes NJ, Gaynanova I. An update on the iglu software package for interpreting continuous glucose monitoring data. Diabetes Technol Ther. 2024;26(12):939–50. https://doi.org/10.1089/dia.2024.0154.

Article  PubMed  Google Scholar 

Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–80. https://doi.org/10.2337/dc18-1581.

Article  PubMed  PubMed Central  Google Scholar 

Kong YW, Yuan CY, Kiburg K, et al. Treatment satisfaction with Omnipod DASH in adults with type 1 diabetes: a nonblinded 1:1 randomized controlled trial. J Clin Endocrinol Metab. 2024;109(8):1984–95. https://doi.org/10.1210/clinem/dgae088.

Article  PubMed  PubMed Central  Google Scholar 

Stocco A, Trawley S, Kong YW, et al.